Asgard Therapeutics
asgardthx.com
Actively hiring
Cell & Gene Therapy
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$32.4M
1 round on record
Latest round
$32.4M
Series A · Mar 2024 · 2 yr ago
Team
51-200
employees, estimated range
Backers
1
Industrifonden
The money's age
Long since its last round
30 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 14
New executive Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative 'personalized off-the-shelf' immunot… · YahooFinance
Mar 25, 2025
New executive Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer · streetinsider.com
Mar 14, 2024
Raised a round Series A $32.4M · led by RV Invest
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Mar 2024 | $32.4M | RV Invest lead, Johnson lead, Inc lead, Novo Holdings, Boehringer Ingelheim Venture Fund, Industrif | asgardthx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Industrifonden Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy.
Unleashing unconventional antigens for cancer immunotherapy. Learn about our technology.
ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune…
Creating next generation immunotherapy treatments for cancer and autoimmune disease.
Molecular Cell Architecture - Life at the highest resolution. Pixelgen Technologies' mission is to provide insights into biology at the…
News
Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 - its first-in-class, off-the-shelf, gene-based cancer immunotherapy
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median survival When used in combination w
Read more
Report
Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 - its first-in-class, off-the-shelf, gene-based cancer immunotherapy
Read more
Report
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
Asgard's immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a personalized anti-tu
Read more
Report
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
Read more
Report
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative 'personalized off-the-shelf' immunotherapy toward clinical development
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard's lead asset AT-108 into Phase 1 clinical developmentAT-108 is a transformative immunotherapy that triggers a personalized immune response against a patient's tum
Read more
Report
Report
Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy
Highly experienced biopharma executive Dr Cristina Csimma joins Asgard's Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard's team as it progresses IND-enabling stud
Read more
Report
Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalit
Read more
Report
Report
Asgard Therapeutics awarded EIC Transition Grant
Asgard Therapeutics, Lund University and Herlev Hospital secure €2.5m in EIC funding to advance TIL-based immunotherapy. The post Asgard Therapeutics awarded EIC Transition Grant appeared first on Asgard Therapeutics.
Read more
Report
Show more news
Financials
Total raised
$32.4M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2024 | $32.4M | Details |